Table 2.
|
|
WPSS at diagnosis |
WHO criteria at diagnosis of MDS |
AML progression |
Progression of PAP |
Pneumonia |
---|---|---|---|---|---|---|
No. | 6 (35.3%) | 11 (64.7%) | 11 (64.7%) | |||
Mild MDS |
1 |
Very low + low |
RA |
|
|
● |
|
2 |
|
RA |
|
● |
|
|
3 |
|
RA |
● |
|
● |
|
4 |
|
RA |
|
● |
● |
|
5 |
|
RA |
● |
|
|
|
6 |
|
RA |
|
● |
|
|
7 |
|
RA |
|
● |
|
Severe MDS |
8 |
Intermediate |
RA |
|
|
● |
|
9 |
|
RA |
|
● |
● |
|
10 |
|
RA |
|
● |
● |
|
11 |
|
RA |
● |
● |
● |
|
12 |
|
RA |
● |
|
● |
|
13 |
|
RCMD |
|
● |
|
|
14 |
High + very high |
RA |
|
● |
● |
|
15 |
|
RCMD |
● |
● |
|
|
16 |
|
RAEB-1 |
|
● |
● |
17 | RAEB-2 | ● | ● |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; PAP, pulmonary alveolar proteinosis; RA, refractory anemia; RAEB, refractory anemia with blasts; RCMD, refractory anemia with multilineage dysplasia; WHO, World Health Organization; WPSS, WHO classification-based prognostic scoring system.